Generic Ornidazole

Buy Generic Ornidazole () without prescription in Canada

In our Canadian pharmacy, you can buy Ornidazole without a prescription, with delivery across Canada within 5‑14 days. Discreet and anonymous packaging.

Ornidazole is a synthetic nitroimidazole antimicrobial and antiprotozoal agent used to treat a variety of infections caused by anaerobic bacteria and certain protozoa. It works by entering the microbial cell and undergoing reduction of its nitro group by bacterial nitroreductases, forming reactive intermediates that damage DNA and inhibit nucleic acid synthesis, ultimately leading to cell death. It is effective against Trichomonas vaginalis, Entamoeba histolytica, Giardia lamblia, and a range of anaerobic bacteria including Bacteroides, Clostridium, and Helicobacter pylori.

Usual adult dose: For trichomoniasis, a single oral dose of 1–1.5 g (2–3 tablets of 500 mg) is taken in the evening. For amoebiasis and giardiasis, 500 mg twice daily for 5–10 days is typical. For anaerobic bacterial infections, 500 mg every 12 hours for 5–14 days is recommended. The tablets should be swallowed whole with a full glass of water, preferably after meals to reduce gastrointestinal upset. The maximum single dose is 1.5 g, and the total daily dose should not exceed 2.5 g.

Dosage form: Film‑coated oral tablet, 500 mg.

Onset of action: Ornidazole is rapidly absorbed, with peak plasma concentrations reached within 2 to 3 hours of an oral dose. Clinical improvement, such as relief of symptoms, is usually seen within 48 to 72 hours of starting therapy, though the full course must be completed to eradicate the infection.

Duration of action: The elimination half‑life of ornidazole is approximately 12 to 14 hours, allowing twice‑daily dosing. Therapeutic concentrations are maintained above the minimum inhibitory concentration (MIC) for susceptible organisms throughout the dosing interval.

Alcohol recommendation: Alcohol consumption must be strictly avoided during treatment with Ornidazole and for at least 3 days after the last dose. Ornidazole, like other nitroimidazoles, can cause a disulfiram‑like reaction when combined with alcohol, leading to severe flushing, nausea, vomiting, tachycardia, and hypotension. Patients must abstain from all alcoholic beverages and alcohol‑containing products (e.g., certain cough syrups, mouthwashes) during therapy.

Most common side effects: Nausea, vomiting, epigastric discomfort, metallic taste, dry mouth, diarrhoea, headache, and dizziness. Darkening of the urine is a harmless effect of the drug. Rare but serious adverse effects include peripheral neuropathy (tingling, numbness, or pain in the hands or feet), seizures, leukopenia, and severe hypersensitivity reactions. Prolonged or repeated courses increase the risk of neurotoxicity.

Would you like to try Ornidazole without a prescription?

General Information about Ornidazole

• INN (International Nonproprietary Name): Ornidazole
• Brand names available in Canada: Ornidazole is not approved for marketing in Canada. No brand‑name or generic ornidazole products are currently listed in the Health Canada Drug Product Database. It is, however, widely available in many other countries under brand names such as Tiberal® (Roche), Ornida®, and Ornigil®, as well as generic formulations. Our pharmacy supplies internationally sourced ornidazole tablets through the international supply chain for personal importation.
• ATC code: P01AB03 (ornidazole; nitroimidazole derivatives for amoebiasis and other protozoal diseases) or J01XD03 (for systemic antibacterial use)
• Dosage forms and strengths: Film‑coated oral tablets: 500 mg. Some international markets also supply 250 mg tablets and injectable formulations.
• Manufacturers in Canada: None. Ornidazole is not manufactured in Canada. Internationally, it is produced by various pharmaceutical companies, including Abbott Laboratories, Zentiva, and generic manufacturers. Our pharmacy obtains the medication through the international supply chain for personal use.
• Registration status in Canada: Not marketed in Canada. Ornidazole has not been issued a Notice of Compliance by Health Canada and is not listed in the Drug Product Database. It may be accessible under the Health Canada Special Access Programme (SAP) for serious infections when conventional therapies are unsuitable. Otherwise, it is imported for personal use under a valid prescription.
• OTC / Rx classification: Prescription only (Rx). A valid prescription from a licensed Canadian healthcare professional is required. Our pharmacy fulfills this prescription for the internationally sourced product.

Mechanism of Action and Pharmacology

Ornidazole is a second‑generation 5‑nitroimidazole derivative, structurally related to metronidazole but with a longer elimination half‑life. Its mechanism of action involves diffusion into susceptible bacteria and protozoa, where the nitro group of the drug is reduced by low‑redox‑potential ferredoxin or flavodoxin. This reduction generates cytotoxic short‑lived free radicals and reactive intermediates that interact with DNA, causing strand breakage, loss of helical structure, and inhibition of nucleic acid synthesis. The result is bactericidal and protozoacidal activity. Unlike metronidazole, ornidazole has a slightly broader spectrum and a longer duration of action, which allows for less frequent dosing and shorter treatment courses for some infections. It is active against a wide range of obligate anaerobes (Bacteroides fragilis, Clostridium difficile, Clostridium perfringens, Peptostreptococcus) and microaerophilic organisms (Helicobacter pylori), as well as protozoal pathogens Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia.

After oral administration, ornidazole is rapidly and completely absorbed, with a bioavailability exceeding 90%. Peak plasma concentrations of approximately 10 μg/mL are reached 2–3 hours after a single 500 mg dose. The drug is widely distributed in body fluids and tissues, including the central nervous system, where cerebrospinal fluid levels reach approximately 60–80% of concurrent plasma concentrations. Ornidazole is extensively metabolised in the liver, primarily by hydroxylation and conjugation, to several inactive metabolites. The elimination half‑life is 12–14 hours in adults with normal hepatic function, which is significantly longer than that of metronidazole (6–8 hours), supporting twice‑daily dosing. Approximately 60% of an oral dose is excreted in the urine (mainly as metabolites) and 20% in the faeces. In patients with severe hepatic impairment, the half‑life may be prolonged, and dose adjustment may be necessary.

Indications

• Trichomoniasis: Single‑dose treatment of urogenital trichomoniasis caused by Trichomonas vaginalis in both men and women. Ornidazole is highly effective and well‑tolerated, with cure rates comparable to metronidazole.
• Amoebiasis: Treatment of intestinal amoebiasis (including amoebic dysentery) and extra‑intestinal amoebiasis (including amoebic liver abscess) caused by Entamoeba histolytica. A 5‑ to 10‑day course is usually curative.
• Giardiasis (lambliasis): Treatment of giardiasis caused by Giardia lamblia. Ornidazole achieves rapid symptom resolution and high parasitological cure rates.
• Bacterial vaginosis: As an alternative or adjunctive therapy for bacterial vaginosis associated with Gardnerella vaginalis and other anaerobes.
• Anaerobic bacterial infections: For the treatment of serious infections caused by susceptible anaerobic bacteria, including intra‑abdominal infections, pelvic inflammatory disease, wound infections, and periodontitis. Ornidazole is often used in combination with other antibiotics for mixed aerobic‑anaerobic infections.
• Helicobacter pylori eradication: As part of combination regimens for the eradication of H. pylori in peptic ulcer disease, particularly in regions where metronidazole resistance is prevalent.
• Surgical prophylaxis: For the prevention of postoperative anaerobic infections in colorectal and gynaecological surgery.

Important Warnings and Precautions

At‑risk groups

• Pregnancy: Ornidazole should be used during pregnancy only if the potential benefit clearly outweighs the potential risk to the foetus. Nitroimidazoles cross the placental barrier, and although no teratogenic effects have been conclusively demonstrated in humans, they are generally avoided during the first trimester. The single‑dose regimen for trichomoniasis is not recommended during pregnancy. If treatment is necessary, it should be administered under strict medical supervision, preferably after the first trimester.
• Breastfeeding: Ornidazole is excreted in human breast milk in amounts similar to those in maternal plasma. Because of the potential for adverse effects in the nursing infant, including mutagenicity and carcinogenicity concerns based on animal data, breastfeeding should be interrupted during treatment and for at least 3 days after the last dose. A decision must be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of the medication to the mother.
• Paediatrics: Safety and efficacy in children have not been established in controlled clinical trials, and ornidazole is not approved for paediatric use in most jurisdictions. However, it is sometimes used off‑label in children over 6 years for specific indications such as amoebiasis or giardiasis, with weight‑based dosing (typically 25–40 mg/kg/day in divided doses). Use in children should be managed by a paediatric infectious disease specialist.
• Elderly: No specific dose adjustment is required for age alone. However, elderly patients may have decreased hepatic or renal function, and they should be monitored for adverse effects, particularly neurological symptoms. Caution is advised.
• Hepatic impairment: Ornidazole is metabolised in the liver. In patients with severe hepatic impairment, the elimination half‑life may be prolonged, and drug accumulation may occur. The dose should be reduced, or the dosing interval extended, based on the degree of hepatic dysfunction. Liver function tests should be monitored periodically.
• Renal impairment: No dose adjustment is required for patients with mild to moderate renal impairment. However, in patients with severe renal failure (creatinine clearance below 10 mL/min), the half‑life of ornidazole metabolites is prolonged, and accumulation of potentially neurotoxic metabolites may occur. The drug should be used with caution, and the dosing interval may need to be extended.
• Neurological effects: Peripheral neuropathy (paraesthesia, pain, weakness, ataxia) and convulsions have been reported with nitroimidazoles, particularly with prolonged or repeated courses. Patients should be advised to report any neurological symptoms immediately. If neuropathy or seizures occur, ornidazole should be discontinued promptly.
• Haematological effects: Reversible leukopenia and thrombocytopenia have been observed in rare cases. Complete blood counts should be monitored during prolonged therapy. In patients with pre‑existing blood dyscrasias, ornidazole should be used with caution.
• Candidiasis: As with other broad‑spectrum antimicrobials, prolonged use of ornidazole may result in overgrowth of non‑susceptible organisms, particularly Candida species. Superinfection should be treated appropriately.
• Disulfiram‑like reaction with alcohol: Ornidazole can cause a severe disulfiram‑like reaction (intense flushing, throbbing headache, nausea, vomiting, tachycardia, and hypotension) when alcohol is consumed. Patients must be strictly warned to avoid all alcoholic beverages and alcohol‑containing products (e.g., certain mouthwashes, cough syrups) during treatment and for at least 3 days after the last dose. This reaction can be dangerous and may require hospitalisation.
• Allergy: Do not take Ornidazole if you have a known hypersensitivity to ornidazole, other nitroimidazole derivatives (e.g., metronidazole, tinidazole), or any excipient in the tablet formulation. Cross‑sensitivity among nitroimidazoles may occur.

Driving and alcohol

Ornidazole may cause dizziness, drowsiness, and visual disturbances. Patients should not drive, operate heavy machinery, or engage in hazardous activities until they know how the medication affects them. Alcohol must be completely avoided during treatment and for at least 3 days after the last dose. The combination of ornidazole and alcohol can provoke a severe and potentially life‑threatening disulfiram‑like reaction.

Dosage Instructions

• Trichomoniasis (adults): A single oral dose of 1–1.5 g (2–3 tablets of 500 mg) taken in the evening, with food, preferably after dinner. Both sexual partners should be treated simultaneously to prevent reinfection.
• Amoebiasis (adults): 500 mg twice daily for 5–10 days, depending on the severity and site of infection. For amoebic liver abscess, a longer course of up to 10 days is recommended. Aspiration or surgical drainage may also be required.
• Giardiasis (adults): 500 mg twice daily for 5–7 days.
• Anaerobic bacterial infections (adults): 500 mg every 12 hours for 5–14 days, in combination with an appropriate aerobic antibiotic for mixed infections. The duration depends on the clinical response and site of infection.
• Bacterial vaginosis (adults): 500 mg twice daily for 5–7 days, or 1–1.5 g as a single dose, as an alternative to metronidazole.
• Surgical prophylaxis (adults): 1 g as a single dose 1–2 hours before surgery, in combination with an antibiotic active against aerobic bacteria.
• Administration: Swallow the tablet whole with a full glass of water, preferably after a meal to reduce gastrointestinal upset. Do not crush or chew. Complete the full prescribed course of therapy, even if symptoms improve earlier. If you miss a dose, take it as soon as remembered with food; if it is close to the time of the next dose, skip the missed dose and resume the regular schedule. Do not double the dose.

Side Effects and Contraindications

• Very common side effects (≥ 10%): Nausea, vomiting, epigastric discomfort, and metallic or bitter taste in the mouth. These are usually mild and resolve after the course is completed.
• Common side effects (1‑10%): Diarrhoea, dry mouth, headache, dizziness, and dark‑coloured urine (due to a metabolite, which is harmless).
• Uncommon but serious side effects: Peripheral neuropathy (tingling, numbness, or weakness in the extremities; may be irreversible), seizures, leukopenia, thrombocytopenia, and severe hypersensitivity reactions (angioedema, anaphylaxis). Prolonged or repeated courses increase the risk of neurotoxicity.
• Contraindications: Known hypersensitivity to ornidazole, other nitroimidazoles, or any excipient. Pregnancy (first trimester). Breastfeeding (therapy should be interrupted for the duration of treatment and 3 days after). Severe hepatic impairment with encephalopathy. Active neurological disease (e.g., epilepsy, multiple sclerosis, peripheral neuropathy). History of blood dyscrasias. Concomitant use with alcohol (during and up to 3 days after treatment).

Drug Interactions

• Alcohol — contraindicated: The combination can provoke a severe disulfiram‑like reaction. Alcohol must be avoided during treatment and for at least 3 days afterwards.
• Warfarin and other coumarin anticoagulants — monitor closely: Ornidazole may potentiate the anticoagulant effect of warfarin, increasing the risk of bleeding. The INR should be monitored before and during therapy, and the warfarin dose adjusted as needed.
• Lithium — increased lithium toxicity: Ornidazole can increase plasma lithium concentrations, potentially leading to lithium toxicity. Lithium levels should be monitored, and the lithium dose may need to be reduced.
• Phenytoin and fosphenytoin — moderate interaction: Ornidazole may inhibit the metabolism of phenytoin, increasing its plasma concentration and the risk of phenytoin toxicity. Phenytoin levels should be monitored.
• Fluorouracil — increased toxicity: Ornidazole may reduce the clearance of fluorouracil, increasing its toxicity (bone marrow suppression, gastrointestinal toxicity). Concomitant use should be avoided or undertaken with close monitoring.
• Cimetidine — possible increased ornidazole levels: Cimetidine, a histamine H2‑receptor antagonist, may inhibit the hepatic metabolism of ornidazole, potentially increasing its plasma concentration and the risk of adverse effects.
• Oral contraceptives: Ornidazole does not significantly reduce the efficacy of hormonal contraceptives, but as a general precaution, some clinicians recommend additional barrier contraception during treatment.
• Laboratory tests: Ornidazole may interfere with certain assays for serum hepatic enzymes (e.g., ALT, AST) if measured by spectrophotometric methods. Inform the laboratory of ornidazole use.

Practical Advice

• Administration: Take Ornidazole with food or immediately after a meal to reduce stomach upset. Swallow the tablet whole with water; do not crush or chew. If you are being treated for a sexually transmitted infection (e.g., trichomoniasis), ensure that your sexual partner(s) are also treated to prevent reinfection. Complete the entire prescribed course, even if you feel better before it is finished. Strictly avoid all alcoholic beverages and alcohol‑containing products during treatment and for 3 days after the last dose.
• Monitoring: No routine laboratory monitoring is required for short‑term therapy in healthy individuals. For prolonged courses (beyond 10 days), complete blood counts and liver function tests should be monitored periodically. Patients on warfarin should have their INR checked before and during therapy. Report any neurological symptoms (tingling, numbness, pain in the hands or feet, or seizures) immediately.
• Storage: Store at room temperature (15‑30 °C) in a dry place, protected from moisture and light. Keep the container tightly closed and out of the reach and sight of children.
• Lifestyle: Because alcohol is strictly forbidden during treatment, plan your therapy to avoid social or occupational pressures to drink. Drink plenty of water to help clear the infection. If you are being treated for giardiasis or amoebiasis, pay careful attention to hand hygiene and avoid preparing food for others to prevent the spread of infection. If you experience severe or persistent nausea, vomiting, headache, or confusion, contact your doctor immediately.
• Missed dose: If you miss a dose, take it as soon as you remember with food. If it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not double the dose.
• When to seek medical review: Stop taking Ornidazole and contact your doctor immediately if you develop signs of peripheral neuropathy (persistent tingling, burning, or numbness), seizures, signs of an allergic reaction (rash, hives, swelling of the face, lips, tongue, or difficulty breathing), or signs of a severe disulfiram‑like reaction (flushing, throbbing headache, severe nausea/vomiting, rapid heartbeat) after accidental alcohol ingestion. If you are pregnant or become pregnant during therapy, inform your doctor.
• Disposal: Return unused or expired medication to a pharmacy for safe disposal. Do not flush down the toilet or discard in household waste.

Alternative Medications

• Metronidazole (Flagyl®): The most widely used nitroimidazole, approved in Canada for trichomoniasis, amoebiasis, giardiasis, bacterial vaginosis, and anaerobic infections. Ornidazole offers a longer half‑life, allowing less frequent dosing, and is often better tolerated with fewer gastrointestinal and neurological side effects. However, metronidazole remains the first‑line agent in most Canadian guidelines due to its well‑established efficacy and availability.
• Tinidazole (Tindamax®): Another second‑generation nitroimidazole with a half‑life similar to ornidazole, approved in Canada for trichomoniasis, giardiasis, and amoebiasis. It is also given as a single dose for some indications and may have a better tolerability profile than metronidazole.
• Secnidazole (Solosec®): A newer nitroimidazole with an even longer half‑life, allowing for a single‑dose treatment of bacterial vaginosis and trichomoniasis. Not yet widely available in Canada, but may be sourced internationally.
• Nitazoxanide (Alinia®): A thiazolide antiprotozoal used for giardiasis and cryptosporidiosis. It is an alternative when nitroimidazoles are not tolerated or contraindicated.
• Paromomycin (Humatin®): An aminoglycoside antibiotic used for intestinal amoebiasis, especially during pregnancy, and as a luminal amoebicide to eliminate cysts.
• Non‑pharmacological measures: For gastrointestinal protozoal infections, meticulous hand hygiene, proper food and water sanitation, and avoidance of contaminated sources are critical to prevent infection and reinfection. For sexually transmitted infections, partner notification and treatment are essential.

Clinical Efficacy

Ornidazole has been extensively studied in numerous clinical trials worldwide and has demonstrated high efficacy for the treatment of protozoal and anaerobic infections. For trichomoniasis, a single 1.5 g dose achieves parasitological cure rates of over 95%, comparable to a multi‑day course of metronidazole. In amoebiasis, ornidazole 500 mg twice daily for 5‑10 days results in clinical and parasitological cure in approximately 90‑95% of patients, including those with amoebic liver abscess. For giardiasis, ornidazole is highly effective, with cure rates exceeding 90% after a 5‑day course. In anaerobic bacterial infections, ornidazole used in combination with an appropriate aerobic antibiotic provides clinical success rates of 85‑95%. The drug’s longer elimination half‑life allows for convenient twice‑daily dosing and, for trichomoniasis, a single‑dose regimen, which significantly improves patient compliance. Its tolerability profile, with a lower incidence of metallic taste and neurological side effects compared with metronidazole, makes it an attractive alternative. However, because ornidazole is not approved in Canada, it is reserved for situations where first‑line agents (metronidazole, tinidazole) are not appropriate or have failed, and its use must be guided by a physician familiar with its pharmacokinetics and safety profile.

Important:

Ornidazole is a prescription antimicrobial and antiprotozoal agent that must be used under the supervision of a qualified healthcare professional. It is not approved for marketing in Canada and is imported for personal use under a valid prescription. Alcohol must be completely avoided during treatment and for at least 3 days after the last dose, as the combination can cause a severe and potentially dangerous disulfiram‑like reaction. Neurological side effects, including peripheral neuropathy and seizures, have been reported, especially with prolonged or repeated courses. If you experience tingling, numbness, pain in the hands or feet, or convulsions, discontinue the medication and seek immediate medical attention. This drug should not be used during the first trimester of pregnancy or while breastfeeding. If you have liver disease, a history of seizures, or blood disorders, inform your doctor before starting therapy. This information is not a substitute for professional medical advice, diagnosis, or treatment.

Get Generic Ornidazole - Shipping across Canada